Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 20530873 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Eke I, et al. (2010) PINCH1 regulates Akt1 activation and enhances radioresistance by inhibiting PP1alpha. J Clin Invest 120, 2516-27 20530873
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

T308-p - Akt1 (mouse) ▲
Orthologous residues
Akt1 (human): T308‑p, Akt1 (mouse): T308‑p, Akt1 (rat): T308‑p, Akt1 (fruit fly): T423‑p, Akt1 (cow): T308‑p
Characterization
 Methods used to characterize site in vivo:  mutation of modification site, phospho-antibody, western blotting
 Disease tissue studied:  colorectal cancer, colorectal carcinoma, lung cancer, non-small cell lung cancer, pancreatic cancer, pancreatic carcinoma
 Relevant cell lines - cell types - tissues:  A431 (epithelial), A549 (pulmonary), DLD1 (intestinal), HCT15 (intestinal), HeLa (cervical), MIA PaCa-2 (pancreatic), NCI-H1299 (pulmonary), PaTu (pancreatic)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
LIMS1 (mouse) increase LIMS1 -/- cells decreases
LIMS1 (human) increase LIM1 siRNA decreases

S473-p - Akt1 (mouse) ▲
Orthologous residues
Akt1 (human): S473‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
 Methods used to characterize site in vivo:  mutation of modification site, phospho-antibody, western blotting
 Disease tissue studied:  colorectal cancer, colorectal carcinoma, lung cancer, non-small cell lung cancer, pancreatic cancer, pancreatic carcinoma
 Relevant cell lines - cell types - tissues:  A431 (epithelial), A549 (pulmonary), DLD1 (intestinal), HCT15 (intestinal), HeLa (cervical), MIA PaCa-2 (pancreatic), NCI-H1299 (pulmonary), PaTu (pancreatic)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
LIMS1 (mouse) increase LIMS1 -/- cells decreases
LIMS1 (human) increase LIM1 siRNA decreases
Downstream Regulation
 Effect of modification (process):  apoptosis, altered
 Comments:  regulates radiation survival

S253-p - FOXO1A (mouse) ▲
Orthologous residues
FOXO1A (human): S256‑p, FOXO1A (mouse): S253‑p, FOXO1A (rat): S250‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  colorectal cancer, colorectal carcinoma, lung cancer, non-small cell lung cancer, pancreatic cancer, pancreatic carcinoma
 Relevant cell lines - cell types - tissues:  A431 (epithelial), A549 (pulmonary), DLD1 (intestinal), HCT15 (intestinal), HeLa (cervical), MIA PaCa-2 (pancreatic), NCI-H1299 (pulmonary), PaTu (pancreatic)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
LIMS1 (mouse) increase LIMS1 -/- cells decreases
LIMS1 (human) increase LIM1 siRNA decreases

S197-p - FOXO4 (mouse) ▲
Orthologous residues
FOXO4 (human): S197‑p, FOXO4 (mouse): S197‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  colorectal cancer, colorectal carcinoma, lung cancer, non-small cell lung cancer, pancreatic cancer, pancreatic carcinoma
 Relevant cell lines - cell types - tissues:  A431 (epithelial), A549 (pulmonary), DLD1 (intestinal), HCT15 (intestinal), HeLa (cervical), MIA PaCa-2 (pancreatic), NCI-H1299 (pulmonary), PaTu (pancreatic)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
LIMS1 (human) no change compared to control LIMS1 -/- no change
LIMS1 (mouse) increase LIMS1 siRNA decreases

S9-p - GSK3B (mouse) ▲
Orthologous residues
GSK3B (human): S9‑p, GSK3B iso2 (human): S9‑p, GSK3B (mouse): S9‑p, GSK3B (rat): S9‑p, GSK3B (rabbit): S3‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  colorectal cancer, colorectal carcinoma, lung cancer, non-small cell lung cancer, pancreatic cancer, pancreatic carcinoma
 Relevant cell lines - cell types - tissues:  A431 (epithelial), A549 (pulmonary), DLD1 (intestinal), HCT15 (intestinal), HeLa (cervical), MIA PaCa-2 (pancreatic), NCI-H1299 (pulmonary), PaTu (pancreatic)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
LIMS1 (mouse) no change compared to control LIMS1 siRNA no change


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.